Ratings by Wolfe Research (Andy Chen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | Ionis Pharmaceuticals | IONS | Downgrade | Peerperform (Outperform) |
54.93 (56.14) |
2.2% | Details | |
| 7/16/2026 | Intellia Therapeutics | NTLA | Downgrade | Underperform (Peerperform) |
13.30 (10.81) |
-18.72% | Details | |
| 7/8/2026 | Sarepta Therapeutics | SRPT | Upgrade | Outperform (Peerperform) |
19.79 (16.25) |
-17.89% | Details | |
| 6/10/2026 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2026 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2026 | Pharvaris B.V. | PHVS | New Coverage | Outperform (N/A) |
27.84 (34.02) |
22.2% | Details | |
| 4/8/2026 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
15.92 (19.96) |
25.38% | Details | |
| 4/8/2026 | Dianthus Therapeutics | DNTH | New Coverage | Outperform (N/A) |
86.20 (104.93) |
21.73% | Details | |
| 4/8/2026 | Palisade Bio Inc. | PALI | New Coverage | Outperform (N/A) |
1.91 (2.00) |
4.71% | Details | |
| 4/1/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/31/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Moonlake Immunotherapeutics | MLTX | Upgrade | Outperform (Peerperform) |
16.27 (19.85) |
22% | Details | |
| 3/23/2026 | Celldex Therapeutics | CLDX | Upgrade | Outperform (Peerperform) |
30.90 (35.74) |
15.66% | Details | |
| 3/10/2026 | Vera Therapeutics | VERA | Upgrade | Outperform (Peerperform) |
38.97 (35.55) |
-8.78% | Details | |
| 3/9/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Peerperform (N/A) |
77.51 (134.26) |
73.22% | Details | |
| 1/6/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Oruka Therapeutics | ORKA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Vertex | VRTX | Upgrade | Outperform (Peerperform) |
448.80 (480.17) |
6.99% | Details | |
| 1/6/2026 | Kymera Therapeutics | KYMR | Downgrade | Peerperform (Outperform) |
72.41 (110.55) |
52.67% | Details | |
| 1/6/2026 | Madrigal Pharmaceuticals | MDGL | Downgrade | Peerperform (Outperform) |
588.40 (552.28) |
-6.14% | Details | |
| 1/6/2026 | Alnylam Pharmaceuticals | IMVT | Upgrade | Outperform (Peerperform) |
397.83 (40.15) |
-89.91% | Details | |
| 12/18/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | argenx SE | ARGX | Downgrade | Peerperform (Outperform) |
918.92 (898.10) |
-2.27% | Details | |
| 11/13/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Intellia Therapeutics | NTLA | Downgrade | Peerperform (Outperform) |
9.73 (13.30) |
36.69% | Details | |
| 10/29/2025 | Avidity Biosciences | RNA | Downgrade | Peerperform (Outperform) |
70.00 (11.65) |
-83.36% | Details | |
| 10/10/2025 | Akero Therapeutics | AKRO | Downgrade | Peerperform (Outperform) |
46.49 (54.74) |
17.75% | Details | |
| 9/24/2025 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2025 | 89bio Inc. | ETNB | Downgrade | Peerperform (Outperform) |
8.08 (14.84) |
83.66% | Details | |
| 9/11/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | Alnylam Pharmaceuticals | ALNY | Upgrade | Peerperform (Underperform) |
401.80 (282.41) |
-29.71% | Details | |
| 8/4/2025 | Vera Therapeutics | VERA | Downgrade | Peerperform (Outperform) |
20.95 (38.97) |
86.01% | Details | |
| 7/1/2025 | Verona Pharma | VRNA | New Coverage | Outperform (N/A) |
93.82 (106.91) |
13.95% | Details | |
| 6/17/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
39.78 (84.33) |
111.99% | Details | |
| 6/17/2025 | Sarepta Therapeutics | SRPT | New Coverage | Peerperform (N/A) |
36.18 (16.25) |
-55.09% | Details | |
| 6/17/2025 | Avidity Biosciences | RNA | New Coverage | Outperform (N/A) |
31.37 (70.00) |
123.14% | Details | |
| 6/3/2025 | Blueprint Medicines | BPMC | Downgrade | Peerperform (Outperform) |
101.35 (129.46) |
27.74% | Details | |
| 5/21/2025 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Moonlake Immunotherapeutics | MLTX | Upgrade | Outperform (Peerperform) |
37.62 (19.85) |
-47.24% | Details | |
| 5/7/2025 | Vertex | VRTX | Downgrade | Peerperform (Outperform) |
500.19 (480.17) |
-4% | Details | |
| 4/21/2025 | Intellia Therapeutics | NTLA | Upgrade | Outperform (Peerperform) |
7.23 (9.73) |
34.58% | Details | |
| 3/18/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
18.04 (99.61) |
452.16% | Details | |
| 3/18/2025 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
89.58 (129.46) |
44.52% | Details | |
| 2/4/2025 | Zenas Biopharma | ZBIO | New Coverage | Outperform (N/A) |
8.02 (32.14) |
300.75% | Details | |
| 2/4/2025 | Vera Therapeutics | VERA | New Coverage | Outperform (N/A) |
37.28 (35.55) |
-4.64% | Details | |
| 2/4/2025 | Crinetics | CRNX | New Coverage | Peerperform (N/A) |
40.30 (83.83) |
108.01% | Details | |
| 2/4/2025 | Oruka Therapeutics | ORKA | New Coverage | Outperform (N/A) |
13.45 (90.81) |
575.17% | Details | |
| 2/4/2025 | 89bio Inc. | ETNB | New Coverage | Outperform (N/A) |
9.60 (8.08) |
-15.83% | Details | |
| 2/4/2025 | AnaptysBio | ANAB | New Coverage | Outperform (N/A) |
17.93 (54.71) |
205.13% | Details | |
| 1/3/2025 | Immunovant | IMVT | Downgrade | Peerperform (Outperform) |
25.19 (40.15) |
59.39% | Details | |
| 11/12/2024 | argenx SE | ARGX | Upgrade | Outperform (Peerperform) |
596.00 (918.92) |
54.18% | Details | |
| 11/12/2024 | Alnylam Pharmaceuticals | ALNY | Downgrade | Underperform (Peerperform) |
277.43 (282.41) |
1.8% | Details | |
| 10/1/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2024 | Incyte | INCY | New Coverage | Outperform (N/A) |
65.83 (119.12) |
80.95% | Details | |
| 9/27/2024 | Celldex Therapeutics | CLDX | Downgrade | Peerperform (Outperform) |
36.02 (35.74) |
-0.78% | Details | |
| 9/3/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Peerperform (N/A) |
|
Details | ||
| 8/26/2024 | Kymera Therapeutics | KYMR | Upgrade | Outperform (Peerperform) |
47.78 (110.55) |
131.37% | Details | |
| 8/26/2024 | Moonlake Immunotherapeutics | MLTX | Downgrade | Peerperform (Outperform) |
49.77 (37.62) |
-24.41% | Details | |
| 8/5/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
35.28 (35.74) |
1.3% | Details | |
| 6/11/2024 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
12.17 (19.85) |
63.11% | Details | |
| 6/11/2024 | Akero Therapeutics | AKRO | New Coverage | Outperform (N/A) |
23.02 (46.49) |
101.95% | Details | |
| 6/11/2024 | Madrigal Pharmaceuticals | MDGL | New Coverage | Outperform (N/A) |
244.34 (552.28) |
126.03% | Details | |
| 5/29/2024 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Rapt Therapeutics | RAPT | Downgrade | Peerperform (Outperform) |
4.40 (58.02) |
1218.64% | Details | |
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Peerperform (Outperform) |
47.04 (64.97) |
38.12% | Details | |
| 4/10/2024 | Ionis Pharmaceuticals | IONS | Upgrade | Outperform (Peerperform) |
42.24 (54.93) |
30.04% | Details | |
| 3/20/2024 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Outperform (N/A) |
62.99 (19.85) |
-68.49% | Details | |
| 2/15/2024 | CRISPR Therapeutics | CRSP | New Coverage | Peerperform (N/A) |
72.78 (47.19) |
-35.16% | Details | |
| 2/15/2024 | Kymera Therapeutics | KYMR | New Coverage | Peerperform (N/A) |
35.03 (110.55) |
215.59% | Details | |
| 2/15/2024 | Insmed | INSM | New Coverage | Outperform (N/A) |
26.60 (106.23) |
299.36% | Details | |
| 2/15/2024 | Alpine Immune Sciences | ALPN | New Coverage | Outperform (N/A) |
28.77 (64.97) |
125.83% | Details | |
| 2/15/2024 | Rapt Therapeutics | RAPT | New Coverage | Outperform (N/A) |
24.99 (58.02) |
132.17% | Details | |
| 2/15/2024 | argenx SE | ARGX | New Coverage | Peerperform (N/A) |
386.83 (898.10) |
132.17% | Details | |
| 2/15/2024 | Vertex | VRTX | New Coverage | Outperform (N/A) |
416.04 (500.19) |
20.23% | Details | |
| 2/15/2024 | Intellia Therapeutics | NTLA | New Coverage | Peerperform (N/A) |
26.45 (10.81) |
-59.13% | Details | |
| 2/15/2024 | Roivant Sciences | ROIV | New Coverage | Outperform (N/A) |
10.80 (34.74) |
221.67% | Details | |
| 2/15/2024 | Immunovant | IMVT | New Coverage | Outperform (N/A) |
36.92 (40.15) |
8.75% | Details | |
| 2/14/2024 | Alnylam Pharmaceuticals | ALNY | New Coverage | Peerperform (N/A) |
162.00 (282.41) |
74.33% | Details |
